Registration of the reduced quantity of shares in Nexstim Plc (the last phase) – GlobeNewswire

Company announcement, Helsinki, 24 May 2021 at 11:00 AM (EEST)

Registration of the reduced quantity of shares in Nexstim Plc (the last phase)

The Annual General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO) (Nexstim or Company) resolved on 11 May 2021 to reduce the quantity of Nexstim's shares without reducing share capital by way of issuing new shares and by redemption of Company's own shares, in such a way that each current 100 shares of the Company shall correspond to one share of the Company after the arrangements related to the reduction of the quantity of Company's shares are completed.

Pursuant to the resolution of the Board of Directors of the Company on 21 May 2021 regarding issue / transfer of shares of the Company without consideration, and the annulment of the remaining treasury shares (as set forth in the Company announcement dated 21 May 2021), the annulment of 2773 shares of the Company and the final amount of shares 6 640 616 after all arrangements connected to the reduction of the quantity of shares have now been registered within the Trade Register.

Helsinki, 24 May 2021

NEXSTIM PLC

The Board of Directors

Furtherinformationisavailableonthewebsitewww.nexstim.comorbycontacting:

LeenaNiemist,ChairoftheBoard+35892727170leena.niemisto@nexstim.com

ErikPenserBankAB(CertifiedAdviser)+4684638300certifiedadviser@penser.se

AboutNexstimPlc

Nexstimis a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders.

Nexstimhas developed a world-leading non-invasive brain stimulation technology calledSmartFocus. It is a navigated transcranial magnetic stimulation (nTMS) technology with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.

SmartFocus technology is used inNexstimsproprietary Navigated Brain Therapy (NBT) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT system is CE marked for the treatment of major depression and chronic neuropathic pain.

In addition,Nexstimis commercializing itsSmartFocus based Navigated Brain Stimulation (NBS) system for diagnostic applications. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.Nexstimshares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For moreinformationplease visitwww.nexstim.com

Read the rest here:

Registration of the reduced quantity of shares in Nexstim Plc (the last phase) - GlobeNewswire